Three routes against infection: identification, behaviour and early combined treatment
Identifying an Ebola variant, infected tadpoles choosing cool water and early combined treatment in infant macaques show viral outcomes changing with the virus, host behaviour and intervention timing.
Science··Night
Identifying the outbreak virus comes before the treatment question
Dalhousie University researchers working on the outbreak in Uganda and the Democratic Republic of Congo identified the outbreak virus as a genetically distinct variant of Bundibugyo ebolavirus. The finding published in The Lancet clarifies the identity of the circulating virus. The outbreak had been declared a public health emergency of international concern in May 2026. No vaccine or treatment is approved specifically for Bundibugyo ebolavirus, and the disease is difficult to recognise early. A second paper in the Journal of Infection considers remdesivir triphosphate as a possible drug candidate against the variant. Medical Xpress presents the candidate as a proposal requiring further research. The researchers say clinical trials are under way in Africa. The report presents identification of the outbreak virus and a possible treatment candidate as separate developments. The first concerns the variant's identity; the second concerns a drug option under investigation. Both appear in peer-reviewed journals, while the report lists no approved Bundibugyo-specific treatment.[1]
Infected tadpoles chose cooler water as viral load rose
Agile frog tadpoles infected with ranavirus moved to cooler water than healthy animals. In the BMC Biology study, the higher an individual's viral load, the colder the water it chose; tadpoles kept in constantly cool water also carried markedly less virus at the end. Over five days, infected animals narrowed their temperature choice. The report presents this as a balance consistent with ranaviruses replicating faster in warmth: a tadpole seeks water cool enough to slow the virus and warm enough to preserve its own physiology. Lower temperature can slow growth and development and weaken the immune response. The selected temperature range narrows as viral load rises. The Bundibugyo report describes the virus and a possible drug, while this study follows host behaviour within the environment. The result belongs to tadpoles of one frog species and offers no finding about the fever response in people. It shows viral load and the choice of cool water changing together in these animals.[2]
Early three-part treatment went beyond single therapies in infant macaques
Oregon Health & Science University researchers combined antiretroviral therapy with broadly neutralising antibodies and leronlimab, which blocks the CCR5 receptor. The three components were given to infected infant macaques within 72 hours of infection. Nature Microbiology reports lasting clearance; each component alone had failed to produce the same result. Teams led by Jonah Sacha and Nancy Haigwood carried out the work at the Oregon and California national primate research centres. The evidence covers infant macaques and the 72-hour treatment window. The report gives no number of treated animals. Individual components are approved for people or in clinical trials, while this particular combination remains untested in human newborns. The three reports describe different results: the outbreak virus was identified as a distinct Bundibugyo variant, infected tadpoles chose cooler water and the early three-part regimen cleared HIV infection in infant macaques. These results address virus identification, host behaviour and combined treatment in three separate biological systems.[1], [2], [3]
